Correlating S100B with disease course in a case of new onset, acquired thrombotic thrombocytopenic purpura (TTP): could this be a new predictive biomarker in TTP?. Kuhlman P, Miller P, Farland A, Owen J, Batt K.. J Clin Apher. 2018;():.
A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Hunt R, Yalamanoglu A, Tumlin J, Schiller T, Baek JH, Wu A, Fogo AB, Yang H, Wong E, Miller P, Buehler PW, Kimchi-Sarfaty C.. Blood. 2017;129(7):896-905.
Analysis of intensive care unit admission and sequelae in patients intravenously abusing extended-release oral oxymorphone. Wilson MW, Bonnecaze AK, Dharod A, Miller PJ.. South Med J. 2017;110(3):217-222.
Acute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging. Bonnecaze AK, Wilson MW, Dharod A, Fletcher A, Miller PJ.. Nephrology (Carlton). 2017;():.
These aren't the paraproteins you have been looking for: a case of light chain deposition disease [abstract]. Lampkin A, Miller P, Gallagher T.. Chest. 2017;152(4 Suppl):893A.
Non-lethal Clostridium sordellii bacteraemia in an immunocompromised patient with pleomorphic sarcoma. Bonnecaze AK, Stephens SE, Miller PJ.. BMJ Case Rep. 2016;2016():.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.